The 6 accredited board members are comprised of veterinary and scientific leaders in ophthalmology and clinical trial design.
Sentrx Animal Care, Inc—an animal health company transforming complex biotechnologies into user-friendly care solutions supporting the long-term well-being of animals—has formed its US-based Ophthalmology Scientific and Medical Advisory Board (OSMAB).
According to a company release, the board members consist of veterinary and scientific leaders in ophthalmology and clinical trial design. The board will be chaired by Sarah Atzet, Chief Scientific Officer, PhD and will collaborate with management to accelerate the company's clinical pipeline development nationwide and the use of its platform BioHAnce technology, a patented molecular matrix of cross-linked hyaluronic acid (HA).
"We've assembled a board of prestigious scientific and medical thought leaders to provide Sentrx with relevant and informed counsel in the months and years ahead, as we continue our research and application efforts and development of disruptive innovation in the veterinary ophthalmology space," said Brian Segebrecht, CEO of Sentrx Animal Care.
"Each member brings unique experience in clinical trial design, antiviral modeling, surgical application and overall industry expertise. The board will help ensure we develop and manufacture products that deliver meaningful innovation to the veterinary ophthalmology space,” he added.
The members of the Sentrx OSMAB include:
For each of the member’s full bios, go here: www.sentrxanimalcare.com/OSMAB
Reference
Sentrx Animal Care, Inc. announces formation of their Ophthalmology Scientific and Medical Advisory Board. News release. Sentrx. January 11, 2022. Accessed January 11, 2022. https://www.prnewswire.com/news-releases/sentrx-animal-care-inc-announces-formation-of-their-ophthalmology-scientific-and-medical-advisory-board-301457942.html